Every material Form 8-K Niki BioSolutions, Inc. has filed with the SEC since September 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Niki BioSolutions appointed Thomas Freeburg as its Chief Financial Officer under an employment agreement, with the appointment effective September 1, 2026, for a two-year term that either party can end on 45 days' notice. The filing says his base salary is $250,000, with $25,000 of each monthly payment deferred until the company receives certain funding, and he is eligible for an annual bonus of up to 50% of base salary plus 50,000 stock options at $8.83 per share.
Board appointed Thomas Freeburg as CFO on October 9, 2026, effective as of September 1, 2026
Base salary of $250,000, rising to $275,000 upon receipt of additional company funding
Eligible for an annual bonus of up to 50% of base salary and 50,000 stock options priced at $8.83 per share
Freeburg previously served as CFO of Interpace Biosciences, Inc. from February 2021 through March 2023
Niki BioSolutions entered into an at-the-market offering agreement allowing it to sell up to $1,396,000 of common stock through H.C. Wainwright & Co. and Brookline Capital Markets, under a shelf registration declared effective on October 9, 2026. The company has no obligation to sell any shares, and any sales would dilute existing shareholders and carry a 3.0% placement fee to Wainwright.
Maximum aggregate offering price of up to $1,396,000 of common stock, subject to authorized share availability and Form S-3 eligibility
Placement fee of 3.0% of gross sales price paid to Wainwright on shares sold as sales agent
Wainwright is deemed to have a conflict of interest because its managing director, Dr. Kira Sheinerman, is the Company's largest shareholder and a director; Brookline acts as qualified independent underwriter for no additional compensation
Niki BioSolutions filed its corporate presentation as Exhibit 99.1 to an 8-K for the H.C. Wainwright Global Investment Conference in September 2026. The deck recaps the all-stock merger with DiamiR Biosciences, which closed July 20, 2026, and outlines the company's Alzheimer's blood-testing plans, but it reports no new financial results. For shareholders, the filing is a routine update that restates strategy and timelines the company says cannot be guaranteed.
Presentation furnished as Exhibit 99.1 for the H.C. Wainwright Global Investment Conference, September 2026
Presentation states the DiamiR merger closed July 20, 2026, with DiamiR holding about 70% and Aptorum about 30% of the combined company
Company says its first pharma services customer contract is signed, with revenue generation expected from 3Q 2026
FDA has not approved CogniMIR as of September 2026; clinical validation is planned for 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Niki BioSolutions, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →